Every other industry has figured out how to make influencer marketing work. Pharma figured out how to make it disappear. Somewhere between the fair balance requirement, the MLR review cycle, and the fear of an FDA warning letter, the industry built an influencer program that checks every compliance box — and moves no one. In this session, a pharma brand marketer makes an uncomfortable argument: regulatory caution isn't what's killing pharma influencer strategy. Cowardice dressed up as caution is. Drawing from campaigns that navigated the regulatory landscape without surrendering creative impact, this talk reframes the compliance framework not as a ceiling, but as a brief — the most honest creative brief the industry has ever been handed. Attendees will leave with a new mental model for briefing, selecting, and activating influencers inside a regulated environment, and a clear-eyed view of where the real risk actually lives: not in the post, but in saying nothing at all.
